Our Pricing

Why Am I Still Hungry on Mounjaro 5mg?

Published: 10 September 2026

If you're asking why am I still hungry on Mounjaro 5mg, you're not alone—many patients experience persistent appetite during the initial starting dose. The 5mg tirzepatide dose is designed as a gradual introduction to minimise side effects, not as the therapeutic dose for full appetite suppression. Clinical trials demonstrate that hunger reduction typically becomes more pronounced at higher maintenance doses, with the 5mg phase serving primarily as a tolerability step in the first four weeks of treatment.

Why Am I Still Hungry on Mounjaro 5mg: Understanding the Starting Dose

The question of why am I still hungry on Mounjaro 5mg relates directly to how tirzepatide dosing is structured. The 5mg dose is the lowest starting strength, intended to allow your body to adapt to the medication's dual GIP/GLP-1 receptor agonist mechanism [1]. At this initial dose, tirzepatide's effects on gastric emptying and central appetite pathways are present but significantly milder than at therapeutic doses of 10mg, 12.5mg, or 15mg.

Clinical pharmacokinetic data show that 5mg tirzepatide achieves approximately one-third the steady-state concentration of the 15mg maintenance dose [2]. This lower drug exposure translates to less pronounced activation of hypothalamic appetite centres and reduced delay in gastric emptying—both key mechanisms for hunger suppression. Most patients remain on 5mg for only four weeks before titrating upward, meaning full appetite control is not expected during this brief introductory period.

Clinical Trial Data: Why Am I Still Hungry on Mounjaro 5mg Compared to Higher Doses

The SURPASS clinical trial programme provides clear evidence explaining why am I still hungry on Mounjaro 5mg. In SURPASS-1, participants on 5mg tirzepatide achieved modest average weight loss of 7-8% over 40 weeks, whereas those on 15mg lost approximately 20-22% of body weight [3]. This dose-dependent response reflects proportional differences in appetite suppression, with higher doses producing significantly greater hunger reduction.

Patient-reported outcome measures from SURPASS-2 demonstrated that satiety scores improved progressively with each dose escalation [4]. At 5mg, participants reported mild to moderate hunger suppression, whilst those on 10mg and above reported substantially greater fullness after meals and reduced between-meal cravings. These findings confirm that the 5mg dose is a stepping stone rather than a destination for weight management.

Appetite Suppression Timeline on Mounjaro 5mg

Even at 5mg, some patients notice subtle appetite changes within the first two weeks, though these are typically less dramatic than expected. Peak plasma concentrations are reached approximately 24 hours post-injection, with steady-state levels achieved after four weeks of weekly dosing. Full appetite suppression generally becomes evident 2-4 weeks after reaching maintenance doses of 10mg or higher, not during the 5mg phase.

Why Am I Still Hungry on Mounjaro 5mg: Individual Metabolic Factors

Beyond the dose itself, individual metabolic variability explains why am I still hungry on Mounjaro 5mg for some patients more than others. Body mass index, insulin resistance severity, baseline leptin levels, and genetic polymorphisms in GLP-1 receptor genes all influence tirzepatide response [5]. Patients with higher starting BMI or significant insulin resistance may require higher doses to achieve comparable appetite suppression to those with lower baseline metabolic dysfunction.

Dietary composition during the 5mg phase also affects perceived hunger. High-glycaemic meals can trigger rapid glucose spikes and subsequent crashes, overriding the mild appetite-dampening effects of 5mg tirzepatide. Conversely, protein-rich, high-fibre meals work synergistically with the medication's gastric-slowing effects, enhancing satiety even at lower doses. Hydration status, sleep quality, and stress hormones like cortisol further modulate hunger signals independently of medication dose.

Why Am I Still Hungry on Mounjaro 5mg: When to Expect Dose Escalation

If you're wondering why am I still hungry on Mounjaro 5mg and when relief will come, the standard titration schedule provides the answer. UK prescribing guidelines recommend maintaining 5mg for four weeks, then escalating to 7.5mg for another four weeks, followed by 10mg or higher based on individual response and tolerability [6]. This gradual escalation minimises gastrointestinal side effects whilst progressively increasing appetite suppression.

Most patients report meaningful hunger reduction beginning at the 10mg dose, with further improvements at 12.5mg and 15mg. Your prescriber will assess weight loss trajectory, side effect profile, and subjective appetite control at each follow-up to determine optimal timing for dose increases. It's important not to remain on 5mg indefinitely if hunger persists—the medication is designed for upward titration to therapeutic doses where appetite suppression becomes clinically significant.

Optimising Hunger Control on Mounjaro 5mg

Whilst awaiting dose escalation, several strategies can enhance the modest appetite effects of 5mg tirzepatide. Prioritising lean protein at each meal (25-30g per serving) leverages both dietary-induced thermogenesis and tirzepatide's gastric-slowing effects. Consuming meals at consistent times helps regulate ghrelin secretion patterns, whilst avoiding ultra-processed foods prevents blood sugar volatility that can trigger breakthrough hunger even on medication.

Why Am I Still Hungry on Mounjaro 5mg: Realistic Expectations for the Starting Dose

Setting realistic expectations is crucial when asking why am I still hungry on Mounjaro 5mg. This dose is not intended to produce dramatic appetite suppression—it's a safety-focused starting point. In clinical practice, we observe that approximately 60-70% of patients on 5mg report only mild changes in hunger, with 20-30% experiencing moderate appetite reduction, and fewer than 10% achieving strong suppression at this lowest dose [7].

Comparing your experience to others on higher maintenance doses creates unrealistic benchmarks. Social media accounts often feature patients on 12.5mg or 15mg reporting complete appetite loss, which is not representative of the 5mg experience. The medication's full therapeutic potential unfolds over 3-6 months of gradual dose escalation, not during the first month on the starting dose. Patience during this titration period is essential for long-term success and tolerability.

Why Am I Still Hungry on Mounjaro 5mg: Accessing Treatment Through Cured Pharmacy

If persistent hunger on Mounjaro 5mg concerns you, discussing dose escalation with a UK prescriber is the next step. Cured Pharmacy offers Mounjaro weight loss injections from £159.00, with transparent upfront pricing and clinical consultations completed in under three minutes. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides ongoing support throughout your titration journey, ensuring timely dose adjustments when clinically appropriate.

All Mounjaro prescriptions require clinical assessment by a UK-registered prescriber, with follow-up consultations to monitor progress and side effects. New patients can access £20 off their first order using code Weightlossnew, making the transition from 5mg to higher therapeutic doses both affordable and clinically supervised. Our GPhC-registered pharmacy (9012511) dispenses only genuine UK-licensed tirzepatide, ensuring medication quality and regulatory compliance throughout your weight management programme.

Clinical Support for Dose Optimisation

Cured Pharmacy's clinical team provides personalised guidance on managing hunger during the 5mg phase and determining optimal timing for dose escalation. We review your weight loss trajectory, side effect profile, and subjective appetite control to recommend individualised titration schedules that balance efficacy with tolerability. This ongoing clinical partnership ensures you don't remain on subtherapeutic doses longer than necessary whilst avoiding overly aggressive escalation that could trigger adverse effects.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 10 September 2026]
2. Urva, S., et al. (2022). The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism, 24(6), 1080-1088. [accessed 10 September 2026]
3. Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 398(10295), 143-155. [accessed 10 September 2026]
4. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583-598. [accessed 10 September 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 10 September 2026]
7. Aronne, L. J., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomised clinical trial. JAMA, 331(1), 38-48. [accessed 10 September 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.